Research view
Switch to patient viewGastric and oesophageal cancer: trials that stopped early
Trials on Gastric and oesophageal cancer that stopped early, each with the reason the sponsor wrote in the registry, quoted word for word. Next to them: finished trials whose registry record links a result paper.
Stopped early
131 stopped trials give a reason in the registry, latest registry update first. 5 more give no reason and are not listed.
Terminated
A Study to Investigate the Safety and Tolerability of Intravenous QEQ278 in Patients With Advanced Solid Tumors
Reason given in the registry “Business decision and not related to safety concerns”
Quoted unchanged from ClinicalTrials.gov; record updated 13 Nov 2026.
- Ended
- Jan 2026
- Phase
- Phase 1
- Run by
- Novartis Pharmaceuticals
- Registry record
- NCT05462873
Suspended
Nivolumab and Ipilimumab in Treating Patients With Esophageal and Gastroesophageal Junction Adenocarcinoma Undergoing Surgery
Reason given in the registry “End of Initial Phase of Multi-phase protocol”
Quoted unchanged from ClinicalTrials.gov; record updated 12 Nov 2026.
- Phase
- Phase 2/3
- Run by
- National Cancer Institute (NCI)
- Registry record
- NCT03604991
Terminated
Study of LVGN3616 and LVGN6051±LVGN7409 in Combination With Nab-Paclitaxel or Bevacizumab and Cyclophosphamide in Metastatic Solid Tumors
Reason given in the registry “\<75% participation”
Quoted unchanged from ClinicalTrials.gov; record updated 10 Nov 2026.
- Ended
- Nov 2026
- Phase
- Phase 1
- Run by
- M.D. Anderson Cancer Center
- Registry record
- NCT05075993
Terminated
Feasibility of Auricular Acupressure for Appetite and Weight in Patients With Stage II-IV Gastric, Esophageal, and Pancreatic Cancer
Reason given in the registry “Study closed per SRC Low Accrual Policy.”
Quoted unchanged from ClinicalTrials.gov; record updated 3 Nov 2026.
- Ended
- Jul 2025
- Run by
- University of Washington
- Registry record
- NCT05911243
Suspended
Adaptive Radiation for Abdominopelvic Metastases
Reason given in the registry “Pending interim analysis”
Quoted unchanged from ClinicalTrials.gov; record updated 2 Nov 2026.
- Phase
- Phase 1
- Run by
- Fox Chase Cancer Center
- Registry record
- NCT05880667
Suspended
HEARTS Trial for Thoracic Cancers
Reason given in the registry “Funding issues”
Quoted unchanged from ClinicalTrials.gov; record updated 30 Oct 2026.
- Phase
- Phase 2
- Run by
- University of Wisconsin, Madison
- Registry record
- NCT07132918
Suspended
A Vaccine (Ad5.F35-hGCC-PADRE) for the Treatment of Gastrointestinal Adenocarcinoma
Reason given in the registry “Protocol is with FDA review, waiting for funding to be released”
Quoted unchanged from ClinicalTrials.gov; record updated 28 Oct 2026.
- Phase
- Phase 2
- Run by
- Thomas Jefferson University
- Registry record
- NCT04111172
Terminated
Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination
Reason given in the registry “The Sponsor terminated the trial early for strategic business reasons. This isn't related to any safety/efficacy/clinical activity/benefit-risk concern with petosemtamab. Ongoing participants will have access to treatment outside of this trial.”
Quoted unchanged from ClinicalTrials.gov; record updated 26 Oct 2026.
- Ended
- Oct 2026
- Phase
- Phase 1/2
- Run by
- Merus B.V.
- Registry record
- NCT04868877
Suspended
Non-endoscopic EC Screening Program in Northern Iran
Reason given in the registry “Waiting to receive capsule sponge device from the manufacturer.”
Quoted unchanged from ClinicalTrials.gov; record updated 16 Oct 2026.
- Run by
- Tehran University of Medical Sciences
- Registry record
- NCT02311712
Terminated
Proton Beam Therapy in the Treatment of Esophageal Cancer
Reason given in the registry “The study is no longer relevant to have open to ensure insurance approval for this patient population”
Quoted unchanged from ClinicalTrials.gov; record updated 2 Oct 2026.
- Ended
- Sept 2026
- Run by
- Washington University School of Medicine
- Registry record
- NCT03482791
Suspended
RCT of Mobile Apps & FitBit v. Usual Care
Reason given in the registry “Study is paused for interim analysis.”
Quoted unchanged from ClinicalTrials.gov; record updated 28 Sept 2026.
- Run by
- Weill Medical College of Cornell University
- Registry record
- NCT03623464
Withdrawn
Pharmacokinetics Study of Larotinib in Subjects With Impaired Hepatic Function
Reason given in the registry “Study was withdrawn per sponsor decision after recruitment opened with no participants enrolled.”
Quoted unchanged from ClinicalTrials.gov; record updated 28 Sept 2026.
- Phase
- Phase 1
- Run by
- Sunshine Lake Pharma Co., Ltd.
- Registry record
- NCT05048368
Terminated
Evaluate BL-M17D1 in Patients w/HER2-Expressing/Mutant Advanced or Metastatic Solid Tumors
Reason given in the registry “The decision is based only on the Sponsor's internal portfolio prioritization and resource management considerations and is not due to the investigational product's toxicity considerations.”
Quoted unchanged from ClinicalTrials.gov; record updated 22 Sept 2026.
- Ended
- Jan 2026
- Phase
- Phase 1
- Run by
- SystImmune Inc.
- Registry record
- NCT06714617
Withdrawn
Wet Heparinized Suction for Abdominal Cancer
Reason given in the registry “study no longer proceeding”
Quoted unchanged from ClinicalTrials.gov; record updated 17 Sept 2026.
- Ended
- Nov 2025
- Run by
- H. Lee Moffitt Cancer Center and Research Institute
- Registry record
- NCT05041335
Terminated
Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014).
Reason given in the registry “Trial was rendered as cancelled work ongoing in the book of business.”
Quoted unchanged from ClinicalTrials.gov; record updated 21 Aug 2026.
- Ended
- May 2026
- Phase
- Phase 3
- Run by
- Merck Sharp & Dohme LLC
- Registry record
- NCT04949256
Suspended
Zimberelimab Anti-PD1 +/- Domvanalimab in Resectable Mmrd Gastric Cancer
Reason given in the registry “Gilead's ongoing evaluation of the wider Zimberelimab and Domvanalimab programme, following the outcomes of the STAR-221 study and the discontinuation of EDGE-Gastric studies. No safety concerns have been identified in relation to ZODIAC.”
Quoted unchanged from ClinicalTrials.gov; record updated 21 Aug 2026.
- Phase
- Phase 2
- Run by
- Royal Marsden NHS Foundation Trust
- Registry record
- NCT06250036
Terminated
Multimodal Al for Precision Diagnosis of Esophageal Cancer
Reason given in the registry “local ethics review”
Quoted unchanged from ClinicalTrials.gov; record updated 18 Aug 2026.
- Ended
- Jun 2026
- Run by
- Shanghai Zhongshan Hospital
- Registry record
- NCT07629921
Terminated
18F-FSPG PET/CT as a Non-Invasive Imaging Biomarker for Treatment Response to Chemoradiation in Esophageal Cancer
Reason given in the registry “\<75% participation”
Quoted unchanged from ClinicalTrials.gov; record updated 13 Aug 2026.
- Ended
- Aug 2026
- Run by
- M.D. Anderson Cancer Center
- Registry record
- NCT06549413
Terminated
A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants With Advanced Unresectable or Metastatic Solid Tumors
Reason given in the registry “Following completion of Phase 1b, the Sponsor decided not to initiate Part 2 of the trial.”
Quoted unchanged from ClinicalTrials.gov; record updated 13 Aug 2026.
- Ended
- Apr 2025
- Phase
- Phase 1/2
- Run by
- NextCure, Inc.
- Registry record
- NCT05572684
Terminated
A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer)
Reason given in the registry “The study was closed because the sponsor decided not to continue the development of certain treatment combinations.”
Quoted unchanged from ClinicalTrials.gov; record updated 3 Aug 2026.
- Ended
- Oct 2025
- Phase
- Phase 1/2
- Run by
- Hoffmann-La Roche
- Registry record
- NCT03281369
Terminated
A Study Evaluating Bemarituzumab in Combination With Other Anti-cancer Therapies in Subjects With Previously Untreated Advanced Gastric or Gastroesophageal Junction Cancer.
Reason given in the registry “Sponsor Decision”
Quoted unchanged from ClinicalTrials.gov; record updated 29 Jul 2026.
- Ended
- Nov 2025
- Phase
- Phase 1/2
- Run by
- Amgen
- Registry record
- NCT05322577
Terminated
NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours
Reason given in the registry “The NuTide:303 study was terminated at NuCana's discretion following refinement of the NUC-3373 development strategy.”
Quoted unchanged from ClinicalTrials.gov; record updated 23 Jul 2026.
- Ended
- May 2025
- Phase
- Phase 1/2
- Run by
- NuCana plc
- Registry record
- NCT05714553
Terminated
Oesophagectomy and Chest Wall and Respiratory Function
Reason given in the registry “Study closed before the planned recruitment target was reached because the study period ended before full recruitment could be completed. Recruitment ceased at study closure and data collection was completed for enrolled participants.”
Quoted unchanged from ClinicalTrials.gov; record updated 23 Jul 2026.
- Ended
- Aug 2024
- Run by
- Imperial College London
- Registry record
- NCT03835273
Suspended
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
Reason given in the registry “Drugs unavailable”
Quoted unchanged from ClinicalTrials.gov; record updated 14 Jul 2026.
- Phase
- Phase 1
- Run by
- David Wald
- Registry record
- NCT05400122
Withdrawn
Safety and Efficacy of CEA-Targeted CAR-T Therapy for Relapsed/Refractory CEA+ Cancer
Reason given in the registry “The sponsor requested to terminate the study.”
Quoted unchanged from ClinicalTrials.gov; record updated 10 Jul 2026.
- Ended
- Apr 2024
- Phase
- Phase 1/2
- Run by
- Chongqing Precision Biotech Co., Ltd
- Registry record
- NCT04348643
Terminated
Dose Finding Study of TNO155 in Adult Patients With Advanced Solid Tumors
Reason given in the registry “Business reasons and not due to any safety concerns”
Quoted unchanged from ClinicalTrials.gov; record updated 9 Jul 2026.
- Ended
- Jul 2025
- Phase
- Phase 1
- Run by
- Novartis Pharmaceuticals
- Registry record
- NCT03114319
Terminated
A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification
Reason given in the registry “The Sponsor has made the decision to terminate this study due to the lack of promising efficacy, internal prioritization, and highly competitive landscape.”
Quoted unchanged from ClinicalTrials.gov; record updated 8 Jul 2026.
- Ended
- Apr 2026
- Phase
- Phase 1
- Run by
- BeOne Medicines
- Registry record
- NCT06585488
Terminated
A Study of XMT-2056 in Advanced/Recurrent Solid Tumors That Express HER2
Reason given in the registry “Development discontinued.”
Quoted unchanged from ClinicalTrials.gov; record updated 18 Jun 2026.
- Ended
- May 2026
- Phase
- Phase 1
- Run by
- Day One Biopharmaceuticals, Inc.
- Registry record
- NCT05514717
Terminated
Assessing Timing of Enteral Feeding Support in Esophageal Cancer Patients on Muscle functTion and Survival
Reason given in the registry “halted prematurely on the occasion of a planned sample size reestimation after 200 randomised patients during which an unexpected futility finding was demonstrated”
Quoted unchanged from ClinicalTrials.gov; record updated 8 Jun 2026.
- Ended
- Dec 2025
- Run by
- University Hospital, Gasthuisberg
- Registry record
- NCT03676478
Terminated
Study of PF-07265807 in Participants With Metastatic Solid Tumors.
Reason given in the registry “Pfizer has made an internal business decision to not continue further development of PF-07265807. This decision was not due to major safety concerns or requests from any regulatory authorities.”
Quoted unchanged from ClinicalTrials.gov; record updated 4 Jun 2026.
- Ended
- Nov 2024
- Phase
- Phase 1
- Run by
- Pfizer
- Registry record
- NCT04458259
Sources: ClinicalTrials.gov and the EU Clinical Trials Register. Status, reason, dates and result links are registry fields, shown as the registry gives them.